Latest Us Market News

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.

Pureprofile delivered a record FY26 with $65 million revenue, 25% EBITDA growth, and a 74% surge in platform revenue, driven by international expansion and technology adoption.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.

Unico Silver has reported continued high-grade drill success at its Joaquin Project, pushing mineralisation beyond existing resources while advancing its Pre-Feasibility Study and securing key land holdings.

Amaero Inc. capped FY2026 with a record A$18.1 million revenue, expanded its production capacity, and landed a A$6.5 million US Department of War contract to develop alternative refractory alloy powders.

Carnegie Clean Energy has secured $2.5 million through a share placement, attracting new overseas investors to fund expansion of its CETO wave energy technology at BiMEP in Spain and commercial activities in Europe and the US.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

Imricor Medical Systems has submitted its final 510(k) devices to the FDA, marking a major step towards commercialising its MRI-guided cardiac catheterisation platform in the US.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.